Mark Levandovsky
Hematology & Oncology · Grand Junction, CONPI 1922267285
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,100 of the $7,131 with a category attached, or 85.5%. 19 manufacturers reported payments, led by AbbVie at 52.6% of the total. Reporting peaked in 2021 at $5,319 and has fallen 98.4% since, to $88 in 2025.
Across 47 payments — averaging $151.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Karyopharm Therapeutics Inc.$2K
- Amgen$339
- Comsort, Inc$100
- Novo Nordisk$84
- Genentech USA, Inc.$81
- plus $500 from 13 others
Across 3 payments — averaging $15,551 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$47K
What the payments were for
- Consulting fees$6,10086%
- Food & beverage$1,03114%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 2 | $3,750 |
| Karyopharm Therapeutics Inc. | 2 | $2,276 |
| Amgen | 10 | $339 |
| Comsort, Inc | 1 | $100 |
| Novo Nordisk | 4 | $84 |
| Genentech USA, Inc. | 4 | $81 |
| Eisai Inc. | 2 | $75 |
| Foundation Medicine, Inc. | 1 | $69 |
| Merck | 4 | $61 |
| E.r. Squibb & Sons, L.L.C. | 4 | $60 |
| Lilly USA, LLC | 2 | $46 |
| AstraZeneca(2 entities) | 2 | $40 |
| Novartis | 2 | $37 |
| Pfizer | 2 | $34 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $19 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $17 |
| Cleerly, Inc. | 1 | $15 |
| Tempus AI, Inc | 1 | $14 |
| GSK | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,131 in reported general payments places this provider in the 65th percentile of 169 hematology & oncology providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 12 | $167,067 |
| Repatha SureclickEvolocumab | 29 | $18,177 |
| OzempicSemaglutide | 13 | $15,595 |
| JardianceEmpagliflozin | 17 | $13,842 |
| Celecoxib | 11 | $1,680 |
| Atorvastatin Calcium | 32 | $367 |
| Olmesartan Medoxomil | 11 | $252 |
| Pantoprazole Sodium | 12 | $248 |
| Losartan Potassium | 13 | $225 |
| Morphine Sulfate ErMorphine Sulfate | 12 | $175 |
| Amlodipine Besylate | 17 | $149 |
| Metformin Hcl ErMetformin Hcl | 12 | $66 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $84 | $15,59513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 169 hematology & oncology providers in Colorado.
Other hematology & oncology in Grand Junction
- Amy SchmidtDenver$2.8M
- Yousuf GaffarDenver$963K
- John BurkeAurora$321K
- Manojkumar BupathiLittleton$312K
- Steven SchusterFort Collins$298K
- Douglas ReznickAurora$294K
- Daniel PollyeaAurora$274K
- Robert RifkinDenver$270K
- Christopher BentonEnglewood$249K
- Mabel MardonesDenver$149K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.